On June 15, Bristol Myers Squibb (BMS) China announced that Sotyktu® (deucravacitinib), the world’s first tyrosine kinase 2 (TYK2) allosteric inhibitor, has been approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drugs (DMARDs). It can be used alone or in combination with methotrexate (MTX). This approval makes Sotyktu the only oral small-molecule targeted therapy in China approved for both moderate-to-severe plaque psoriasis and active PsA, offering a new oral targeted treatment option for the broader psoriatic disease (PsD) patient population in China.
"In China, approximately 6% to 13% of psoriasis patients also develop psoriatic arthritis, leading to joint pain, stiffness, functional impairment, and even irreversible disability. Furthermore, PsA commonly affects young and middle-aged adults between 30 and 50 years old, adding to the burden on individuals, families, and society," said Prof. Zeng Xiaofeng, Director of the National Clinical Research Center for Rheumatic and Autoimmune Diseases, Tenured Professor at the Chinese Academy of Medical Sciences & Peking Union Medical College, and the Chinese coordinating investigator for the POETYK PsA-2 Phase III study. "Like psoriasis, PsA is currently incurable and requires long-term medication. Therefore, there is a significant clinical need for highly effective, safe, and convenient oral therapies. The approval of deucravacitinib for PsA brings a much-needed new oral treatment option, which is welcome news for both physicians and patients."
The PsA indication approval for Sotyktu is primarily based on positive results from two global Phase III clinical trials, POETYK PsA-1 and POETYK PsA-2, which demonstrated the efficacy and safety of Sotyktu (6 mg, once daily, oral) in treating adult patients with active PsA. In both trials, Sotyktu demonstrated significant and multi-dimensional improvements in disease symptoms, with clinical benefits sustained through 52 weeks. Key assessment endpoints included ACR20 response (primary endpoint), as well as multi-dimensional secondary endpoints such as Minimal Disease Activity (MDA) response and PASI75 response.
Notably, a post-hoc analysis of the POETYK PsA-1 trial observed an inhibitory effect of Sotyktu on radiographic progression at Week 16. Although the pre-specified analysis did not show a statistically significant difference between the Sotyktu and placebo groups in the mean change from baseline (CfB) in the modified mSvdH score, the post-hoc analysis revealed a statistically significant difference between the two groups. Furthermore, a significantly higher proportion of patients in the Sotyktu group achieved no radiographic progression (defined as a CfB in mSvdH score ≤0 at Week 16) compared to the placebo group.
Across both trials, the overall safety and tolerability of Sotyktu was favorable, consistent with the safety profile established in previous long-term data from patients with moderate-to-severe plaque psoriasis over 5 years of follow-up, with no new safety signals identified.
“From skin to joints, the challenges PsD brings to patients are multifaceted. With the approval for psoriatic arthritis, Sotyktu can offer patients a ‘simplified’ treatment approach, giving them the opportunity to enjoy a higher quality of life. This is both a real-world embodiment of BMS’s patient-centric mission and a reflection of our deep expertise and firm commitment in immunology,” said Mr. Qian Jiang, President of BMS China.”oking ahead, we will continue to explore the value and potential of Sotyktu in more diseases, and remain dedicated to addressing significant unmet needs in immune-mediated diseases, accelerating the introduction of more innovative medicines to benefit Chinese patients, in line with our long-term ‘‘China 2030 Strategy’’commitment.